Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | B0005 | IM / LA |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | N/A | 391417 | IM / LA |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 3RE73 | IM / RA |
No adverse event reported. Reporting this VAERS per Moderna after a temperature excursion, vaccine remained viable after the excursion per Moderna.
psoriasis
mixed hyperlipidemia, alcohol use disorder
triamcinolone, hyrdoxyzine, fluocinolone, betamethasone valerate, nicotine patch, nicotine lozenge, thiamine
no known allergies
N/A